The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 621 | -11,148 |
| Depreciation | 338 | 640 |
| Amortization of intangible assets | 2,711 | 5,421 |
| Amortization of premium/discount on investments | 0 | 0 |
| Amortization of debt discount and debt issuance costs | 843 | 1,664 |
| Amortization of operating right-of-use assets | 140 | 246 |
| Deferred income tax expense (benefit) | 0 | 0 |
| Stock-based compensation | 7,643 | 9,451 |
| Change in fair value of contingent value rights | 0 | 0 |
| Trade accounts receivable | 703 | 12,633 |
| Prepaid expenses and other current assets | 5,153 | -1,803 |
| Inventory | 4,085 | 11,190 |
| Accounts payable | 1,996 | -367 |
| Other accrued liabilities | 2,832 | -3,230 |
| Accrued trade discounts and rebates | 11,930 | 8,445 |
| Accrued returns reserve | -566 | 700 |
| Operating lease liabilities | -412 | -742 |
| Other | 297 | 1,091 |
| Net cash provided by (used in) operating activities | 18,432 | -9,849 |
| Capital expenditures | -71 | -292 |
| Purchases of investments | 0 | 0 |
| Sales and maturities of investments | 0 | 0 |
| Net cash provided by (used in) investing activities | -71 | -292 |
| Proceeds from debt refinancing | 0 | 0 |
| Payment of debt discount | 0 | 0 |
| Proceeds from issuance of employee stock purchase plan shares | 0 | 830 |
| Proceeds from exercise of stock options | 5,161 | 5,833 |
| Proceeds from issuance of warrants | 9,167 | - |
| Repurchase of common stock withheld for taxes | 478 | 8,858 |
| Net cash provided by (used in) financing activities | 13,850 | -2,195 |
| Net cash provided by (used in) in cash, cash equivalents and restricted cash | 32,211 | -12,336 |
| Cash and cash equivalents at beginning of period | 75,744 | - |
| Cash and cash equivalents at end of period | 95,619 | - |
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)